New hope for Tough-to-Treat esophageal cancer?
NCT ID NCT05022654
Summary
This study is testing whether a new drug called SI-B001, when combined with an existing chemotherapy drug (irinotecan), can help control advanced esophageal cancer that has come back or spread after initial treatment. It involves 22 adults whose cancer worsened despite prior immunotherapy. The main goals are to see if the combination is safe and if it shrinks tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anyang Cancer Hospital of Henan Province
Anyang, Henan, China
-
Beijing Cancer Hostital
Beijing, Beijing Municipality, 100142, China
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
-
Suining Central Hospital
Suining, Sichuan, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
-
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Conditions
Explore the condition pages connected to this study.